Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

作者：Jeremy S Abramson, Matthew Ku, Mark P. Hertzberg, Huiqiang Huang, Christopher P. Fox, Huilai Zhang, Dok Hyun Yoon, Won-Seog Kim, Haifaa Abdulhaq, William Townsend, Charles Herbaux, Jan Maciej Zaucha, Qingyuan Zhang, Hung Chang, Yanyan Liu, Chan Y. Cheah, Hervé Ghesquières, Stephen J. Simko, Victor M. Orellana‐Noia, Rogachikova Ta, James Relf, Mark R. Dixon, Martine Kallemeijn, Estefania Mulvihill, Huang Huang, Linda Lundberg, Gareth P. Gregory · 发表于：The Lancet · 年份：2024 · DOI：10.1016/s0140-6736(24)01774-4 · 被引用次数：173 · 研究领域：Lymphoma Diagnosis and Treatment、CAR-T cell therapy research、Cutaneous lymphoproliferative disorders research